Man Group PLC Lineage Cell Therapeutics, Inc. Transaction History

Man Group PLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.2 - $1.53 $3,224 - $4,111	-2,687 Reduced 2.62%	99,709 $149,000
Q4 2022 Feb 14, 2023	BUY	$1.02 - $1.5 $104,443 - $153,594	102,396 New	102,396 $119,000
Q1 2021 May 17, 2021	SELL	$1.77 - $3.1 $42,104 - $73,742	-23,788 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$0.95 - $1.83 $22,598 - $43,532	23,788 New	23,788 $42,000

120

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $91.7M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.